Compugen Ltd. (CGEN)
Q2 2012 Earnings Call
August 7, 2012 10:00 AM ET
Martin Gerstel – Chairman
Mary Haak-Frendscho – Chairperson
Anat Cohen-Dayag – President and CEO
Brian Coleman – Hawk Hill Asset Management
Christopher Hernandez – Gilder Gagnon Howe
Mara Goldstein – Cantor Fitzgerald
Brett Reiss – Janney Montgomery Scott
Ladies and gentlemen, thank you for standing by. Welcome to the Compugen Ltd., Second Quarter 2012 Financial Results Conference call. All participants are at present in a listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. (Operator Instructions)
As a reminder, this conference is being recorded, August 7, 2012. With us online today are Mr. Martin Gerstel, Chairman of the Board, Dr. Anat Cohen-Dayag, President and CEO; Dr. Mary Haak-Frendscho, Chairperson of the Board for Compugen Incorporated and Ms. Dikla Czaczkes Axselbrad, CFO.
I would like to remind everyone that the Safe Harbor language contained in today’s press release also pertains to all content of this conference call. If you have not received a copy of today’s release and would like to do so, please contact Dikla Czaczkes Axselbrad at 972-376-585-95. Mr. Gerstel, would you like to begin?
Yes, thank you very much. And on behalf of all of us with Compugen, welcome to our Q2 2012 conference call. I am now in California at our regionally established monoclonal antibody facility with Dr. Mary Haak-Frendscho, Chairperson of Compugen Inc, while Anat, our CEO; and Dikla, our CFO are at our offices in Israel. Hopefully this geographical difference will not create any problems during our call, but if it does, I apologize in advance.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts